



1 November 2023

Sydney, Australia

2023 AGM Chair Letter to Shareholders

Nyrada Inc (ASX: NYR), a drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases attaches a letter to Shareholders from Non-Executive Chair John Moore.

-ENDS-

About Nyrada Inc

Nyrada is a drug discovery and development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.

Investor & Corporate Enquiries:

Dimitri Burshtein

T: 02 9498 3390

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@automicgroup.com.au


Media Enquiries:

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111

E: cstrong@citadelmagnus.com



Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.



1 November 2023

Dear Fellow Shareholders,

On Monday 20 November 2023, the Company will be holding its 2023 Annual General Meeting (AGM). Nyrada is at an important juncture of its development, so I urge you to attend this meeting, vote, and ask questions. If you are unable to attend, please lodge your proxy votes and if you have any, send in your questions.

Details of the AGM and voting is below, but no matter your voting intentions, **I strongly urge you to vote so to exercise your shareholder rights.**

Annual Report, Notice of Meeting, and Sample Proxy Form

A copy of our 2023 Annual Report, 2023 [AGM Notice of Meeting](#), and Sample Proxy Form is available [on our website or at this link](#).

Depending on your communication preferences, you may have received your proxy voting form by mail. If you have received one by mail, please complete it and return it, or otherwise please access the electronic voting mechanism described in the [Notice of Meeting](#).

Resolutions for Consideration

As you can see from our [Notice of Meeting](#), there are 9 resolutions for shareholder consideration.

Resolutions 1 through 6 relate to the re-election of your Board. Your Board has a sterling and uncommon (for an ASX biotechnology company) mix of capabilities across local and global pharmaceutical and capital markets. The composition of your Board is one of the key strategic advantages of the Company and acts as an intellectual and relationship force multiplier for the management team.

Subject to the relevant nominated Director abstaining, the Board unanimously recommend that you vote in favour of these resolutions.

Resolution 7 relates to the Company's securities issue capacity where the Company is seeking your approval to issue a further 10% of issued capital, should it be required, pursuant to ASX Listing Rule 7.1A.

The Board and I unanimously recommend that you vote in favour of this resolution.



Resolution 8 relates to the approval to issue Incentive Securities to Dr. Gisela Mautner, one of the directors of the Company. These Incentive Securities are under the Equity Incentive Plan previously approved by Shareholders. Dr. Mautner is a recent but important addition to your Board, and she brings extensive medical and pharmaceutical experience.

With the exception of Dr. Maunter who abstained, the Board and I unanimously recommend that you vote in favour of this resolution.

Resolution 9 relates to an update to the Company's Certificate of Incorporation as required under the Delaware General Corporation Law.

The Board and I unanimously recommend that you vote in favour of this resolution.

Further information on these resolutions, including an explanatory statement with further detail is available in our [Notice of Meeting](#) available [on our website or at this link](#).

Annual General Meeting

The Nyrada AGM will be held at 10.00am (AEDT) on Monday 20 November 2023. The AGM will be a hybrid meeting comprising a virtual meeting as well as an in-person meeting.


For those Shareholders or CDI Holders wishing to attend in person, vote, and ask questions, the meeting will be held in the offices of Automic, Nyrada's registry services provider, located at Level 5, 126 Phillip Street, Sydney NSW Australia. For those Shareholders or CDI Holders wishing to attend virtually, please refer to the [Notice of Meeting](#) for instructions on how to access the virtual meeting.

Meeting Questions

Should you have any questions to put to the meeting, I would encourage you to submit questions in advance of the Meeting. Questions must be submitted in writing to David Franks, Company Secretary, at David.Franks@automicgroup.com.au no later than close of business on Friday 10 November 2023.

The Board and I thank you for your ongoing support of Nyrada. I again urge you to exercise your shareholder rights and vote at the meeting or by proxy. This is an important time for the Company, and it is an honour to lead your Board and represent your interests.

Our future is before us.



John Moore
Non-Executive Chair